151 related articles for article (PubMed ID: 16386435)
1. CT and PET imaging in non-small cell lung cancer.
Knoepp UW; Ravenel JG
Crit Rev Oncol Hematol; 2006 Apr; 58(1):15-30. PubMed ID: 16386435
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
[TBL] [Abstract][Full Text] [Related]
3. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CT and positron emission tomography/CT coregistered images in planning radical radiotherapy in patients with non-small-cell lung cancer.
Macmanus M; D'Costa I; Everitt S; Andrews J; Ackerly T; Binns D; Lau E; Ball D; Weih L; Hicks RJ
Australas Radiol; 2007 Aug; 51(4):386-93. PubMed ID: 17635480
[TBL] [Abstract][Full Text] [Related]
5. Is 18F FDG PET-CT cost effective in lung cancer?
Buscombe J; O'Rourke E
Expert Rev Anticancer Ther; 2007 Apr; 7(4):471-6. PubMed ID: 17428168
[TBL] [Abstract][Full Text] [Related]
6. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives.
Nestle U; Kremp S; Grosu AL
Radiother Oncol; 2006 Nov; 81(2):209-25. PubMed ID: 17064802
[TBL] [Abstract][Full Text] [Related]
7. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer.
Yang W; Fu Z; Yu J; Yuan S; Zhang B; Li D; Xing L; Zhao D; Mu D; Sun X; Fang Y; Huang Y; Li W
Lung Cancer; 2008 Jul; 61(1):35-43. PubMed ID: 18177978
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of advantages of positron emission tomography over computed tomography for N-staging in lung cancer patients.
Ebihara A; Nomori H; Watanabe K; Ohtsuka T; Naruke T; Uno K; Kuwahira I; Eguchi K
Jpn J Clin Oncol; 2006 Nov; 36(11):694-8. PubMed ID: 17068084
[TBL] [Abstract][Full Text] [Related]
9. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K
J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365
[TBL] [Abstract][Full Text] [Related]
10. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
11. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results.
Nomori H; Mori T; Ikeda K; Kawanaka K; Shiraishi S; Katahira K; Yamashita Y
J Thorac Cardiovasc Surg; 2008 Apr; 135(4):816-22. PubMed ID: 18374761
[TBL] [Abstract][Full Text] [Related]
12. CT, positron emission tomography, and MRI in staging lung cancer.
Erasmus JJ; Sabloff BS
Clin Chest Med; 2008 Mar; 29(1):39-57, v. PubMed ID: 18267183
[TBL] [Abstract][Full Text] [Related]
13. Imaging to optimally stage lung cancer: conventional modalities and PET/CT.
Truong MT; Munden RF; Movsas B
J Am Coll Radiol; 2004 Dec; 1(12):957-64. PubMed ID: 17411738
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
[TBL] [Abstract][Full Text] [Related]
15. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.
Podoloff DA; Advani RH; Allred C; Benson AB; Brown E; Burstein HJ; Carlson RW; Coleman RE; Czuczman MS; Delbeke D; Edge SB; Ettinger DS; Grannis FW; Hillner BE; Hoffman JM; Kiel K; Komaki R; Larson SM; Mankoff DA; Rosenzweig KE; Skibber JM; Yahalom J; Yu JM; Zelenetz AD
J Natl Compr Canc Netw; 2007 May; 5 Suppl 1():S1-22; quiz S23-2. PubMed ID: 17509259
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation and staging of patients who have lung cancer.
Hensing TA
Hematol Oncol Clin North Am; 2005 Apr; 19(2):219-35, v. PubMed ID: 15833404
[TBL] [Abstract][Full Text] [Related]
17. Lung-cancer staging with PET-CT.
Bruzzi JF
N Engl J Med; 2009 Oct; 361(16):1606; author reply 1608. PubMed ID: 19828539
[No Abstract] [Full Text] [Related]
18. PET-CT in preoperative staging of lung cancer.
Fischer BM; Lassen U; Højgaard L
N Engl J Med; 2011 Mar; 364(10):980-1. PubMed ID: 21388332
[No Abstract] [Full Text] [Related]
19. Staging of non-small-cell lung cancer with integrated PET and CT.
Miles KA
N Engl J Med; 2003 Sep; 349(12):1188-90; author reply 1188-90. PubMed ID: 14503542
[No Abstract] [Full Text] [Related]
20. PET/CT for staging and monitoring non small cell lung cancer.
Rankin S
Cancer Imaging; 2008 Oct; 8 Spec No A(Spec Iss A):S27-31. PubMed ID: 18852078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
